Unnamed: 0,title,date,stock,sentiment
1038750.0,60 Biggest Movers From Yesterday,2020-05-15 04:53:00-04:00,PSTI,neutral
1038751.0,42 Stocks Moving In Thursday's Mid-Day Session,2020-05-14 12:55:00-04:00,PSTI,neutral
1038752.0,Pluristem Provides 28-Day Follow Up For Ventilator-Dependent COVID-19 Patients under Compassionate Use Program in Israel and U.S.,2020-05-14 08:01:00-04:00,PSTI,positive
1038753.0,15 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-05-11 07:36:00-04:00,PSTI,neutral
1038754.0,96 Biggest Movers From Friday,2020-05-11 05:14:00-04:00,PSTI,neutral
1038755.0,70 Stocks Moving In Friday's Mid-Day Session,2020-05-08 12:43:00-04:00,PSTI,neutral
1038756.0,"The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda",2020-05-08 07:59:00-04:00,PSTI,neutral
1038757.0,17 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-05-08 07:50:00-04:00,PSTI,neutral
1038758.0,38 Stocks Moving in Friday's Pre-Market Session,2020-05-08 07:36:00-04:00,PSTI,neutral
1038759.0,Pluristem Therapeutics shares are trading higher after the company announced the FDA has cleared its investigational new drug application for its Phase 2 coronavirus study.,2020-05-08 07:31:00-04:00,PSTI,positive
1038760.0,Pluristem Therapeutics Reports FDA Clears Co.'s Investigatinoal New Drug Application For Phase 2 Study Of PLX Cells As Treatment Of Severe Coronavirus Cases Compliacted By Acute Respiratory Distress Syndrome,2020-05-08 06:05:00-04:00,PSTI,negative
1038761.0,Pluristem Prices ~1.587M Share Registered Direct Offering At $9.45/Share,2020-05-05 09:57:00-04:00,PSTI,positive
1038762.0,72 Biggest Movers From Yesterday,2020-05-05 04:29:00-04:00,PSTI,neutral
1038763.0,55 Stocks Moving In Monday's Mid-Day Session,2020-05-04 12:39:00-04:00,PSTI,neutral
1038764.0,20 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-05-04 07:44:00-04:00,PSTI,neutral
1038765.0,30 Stocks Moving in Monday's Pre-Market Session,2020-05-04 07:05:00-04:00,PSTI,neutral
1038766.0,20 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-04-30 07:33:00-04:00,PSTI,neutral
1038767.0,35 Stocks Moving in Thursday's Pre-Market Session,2020-04-30 07:11:00-04:00,PSTI,neutral
1038768.0,108 Biggest Movers From Yesterday,2020-04-30 05:30:00-04:00,PSTI,neutral
1038769.0,"Pluristem Therapeutics Shares Spike To Near Session High, Still Down 9.5% For Session; Traders Circulate Apr. 29-Dated European Patent Office Specification For Co.'s 'METHOD AND DEVICE FOR THAWING BIOLOGICAL MATERIAL'",2020-04-29 15:30:00-04:00,PSTI,positive
1038770.0,82 Stocks Moving In Wednesday's Mid-Day Session,2020-04-29 12:50:00-04:00,PSTI,neutral
1038771.0,96 Biggest Movers From Yesterday,2020-04-28 04:22:00-04:00,PSTI,neutral
1038772.0,81 Biggest Movers From Friday,2020-04-27 05:33:00-04:00,PSTI,neutral
1038773.0,Mid-Afternoon Market Update: Dow Rises 150 Points; Pluristem Therapeutics Shares Spike Higher,2020-04-24 14:38:00-04:00,PSTI,positive
1038774.0,54 Stocks Moving In Friday's Mid-Day Session,2020-04-24 12:22:00-04:00,PSTI,neutral
1038775.0,Stocks That Hit 52-Week Highs On Friday,2020-04-24 10:33:00-04:00,PSTI,neutral
1038776.0,"The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO",2020-04-24 08:38:00-04:00,PSTI,positive
1038777.0,Pluristem shares are trading higher after the company received €50 million in non-dilutive financing from the European Investment Bank to support its coronavirus project and Phase III studies.,2020-04-24 08:24:00-04:00,PSTI,positive
1038778.0,Pluristem Therapeutics shares are trading higher after the company announced it has secured a €50 million non-dilutive funding from the European Investment Bank to support its coronavirus project and Phase 3 studies.,2020-04-24 07:12:00-04:00,PSTI,positive
1038779.0,32 Stocks Moving in Friday's Pre-Market Session,2020-04-24 07:11:00-04:00,PSTI,neutral
1038780.0,"Pluristem Therapeutics Secures €50M Non-Dilutive Funding From European Investment Bank To Support Coronavirus Project, Phase 3 Studies",2020-04-24 06:06:00-04:00,PSTI,positive
1038781.0,Pluristem Secures €50 Million Non-Dilutive Financing from the European Investment Bank to Support its COVID-19 Project and Phase III Studies,2020-04-24 06:01:00-04:00,PSTI,positive
1038782.0,76 Biggest Movers From Yesterday,2020-04-24 04:42:00-04:00,PSTI,neutral
1038783.0,35 Stocks Moving in Monday's Pre-Market Session,2020-04-20 07:20:00-04:00,PSTI,neutral
1038784.0,95 Biggest Movers From Friday,2020-04-20 05:00:00-04:00,PSTI,neutral
1038785.0,58 Stocks Moving In Friday's Mid-Day Session,2020-04-17 12:31:00-04:00,PSTI,neutral
1038786.0,"The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant",2020-04-16 08:09:00-04:00,PSTI,neutral
1038787.0,70 Biggest Movers From Yesterday,2020-04-16 04:38:00-04:00,PSTI,neutral
1038788.0,Mid-Afternoon Market Update: Dow Falls 1.5%; Pfenex Shares Plummet,2020-04-15 14:37:00-04:00,PSTI,positive
1038789.0,Pluristem Therapeutics Option Alert: Sep 18 $14 Calls Sweep (2) near the Ask: 500 @ $2.25 vs 70 OI; Earnings 5/4 Before Open [est] Ref=$10.3,2020-04-15 12:46:00-04:00,PSTI,positive
1038790.0,"The Daily Biotech Pulse: Amarin Reports Strong Q1 Vascepa Sales, BeiGene Aces Late-Stage Lung Cancer Study, Glaxo, Sanofi Strike COVID-19 Vaccine Partnership",2020-04-14 07:59:00-04:00,PSTI,negative
1038791.0,86 Biggest Movers From Yesterday,2020-04-14 05:19:00-04:00,PSTI,negative
1038792.0,63 Stocks Moving In Monday's Mid-Day Session,2020-04-13 12:35:00-04:00,PSTI,neutral
1038793.0,Stocks That Hit 52-Week Highs On Monday,2020-04-13 10:25:00-04:00,PSTI,neutral
1038794.0,20 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-04-13 07:39:00-04:00,PSTI,neutral
1038795.0,Pluristem Therapeutics shares are trading higher after the company announced it has treated its first patient suffering from coronavirus complications in the US under the FDA Single Patient Expanded Access Program.,2020-04-13 07:14:00-04:00,PSTI,negative
1038796.0,30 Stocks Moving in Monday's Pre-Market Session,2020-04-13 06:56:00-04:00,PSTI,neutral
1038797.0,Pluristem Expands its Compassionate Use Program: Treated First COVID-19 Patient in U.S. Under FDA Single Patient Expanded Access Program,2020-04-13 06:03:00-04:00,PSTI,positive
1038798.0,100 Biggest Movers From Thursday,2020-04-13 05:18:00-04:00,PSTI,neutral
1038799.0,75 Stocks Moving In Thursday's Mid-Day Session,2020-04-09 13:02:00-04:00,PSTI,neutral
1038800.0,Stocks That Hit 52-Week Highs On Thursday,2020-04-09 10:25:00-04:00,PSTI,neutral
1038801.0,80 Biggest Movers From Yesterday,2020-04-08 04:12:00-04:00,PSTI,neutral
1038802.0,Why Pluristem Therapeutics Trading Higher Today,2020-04-07 14:20:00-04:00,PSTI,neutral
1038803.0,56 Stocks Moving In Tuesday's Mid-Day Session,2020-04-07 12:47:00-04:00,PSTI,neutral
1038804.0,"Pluristem shares are trading higher after the company reported preliminary data from its coronavirus compassionate use program, treating seven patients with acute respiratory failure.",2020-04-07 11:07:00-04:00,PSTI,positive
1038805.0,"UPDATE: Pluristem Reports 100% Survival Rate, 4 Of 6 Patients Demonstrated Improvement In Respiratory Parameters, 3 Of 6 Are 'in advanced stages of weaning from ventilators'",2020-04-07 07:52:00-04:00,PSTI,positive
1038806.0,"Pluristem Reports Preliminary Data From Coronavirus Compassionate Use Program, Treating Seven Patients With Acute Respiratory Failure",2020-04-07 07:51:00-04:00,PSTI,neutral
1038807.0,80 Biggest Movers From Yesterday,2020-03-31 04:15:00-04:00,PSTI,neutral
1038808.0,"Pluristem Therapeutics Shares Spike Higher, Halted On Circuit Breaker, Now Up 26.3% For Session",2020-03-30 14:44:00-04:00,PSTI,positive
1038809.0,Pluristen Says Treated First Three Patients In Israel Under Compassionate Use,2020-03-30 07:32:00-04:00,PSTI,positive
1038810.0,"Pluristem Says Is PReparing For Potential Ramp Up In Production To Supply PLX-PAD Cells For 'Potential Treatment Of' Coronavirus Complications, Says As Implemented Cost Reduction Plan",2020-03-26 08:09:00-04:00,PSTI,neutral
1038811.0,Pluristem Highlights Israeli News Story On Israeli Coronavirus Efforts,2020-03-25 11:08:00-04:00,PSTI,neutral
1038812.0,Pluristem Reports Israeli Ministry Of Health Approved Co.'s Request To Seek Approvals To Treat Coronavirus Infection,2020-03-17 08:40:00-04:00,PSTI,positive
1038813.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,PSTI,negative
1038814.0,"Pluristem Therapeutics Reports Collaboration With Charite University Of Medicine Berlin For Targeting Potential Treatment For Respiratory, Inflammatory Intratissue Complications Caused By Coronavirus Infection",2020-03-12 09:14:00-04:00,PSTI,neutral
1038815.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,PSTI,negative
1038816.0,123 Biggest Movers From Yesterday,2020-03-10 05:57:00-04:00,PSTI,neutral
1038817.0,101 Stocks Moving In Monday's Mid-Day Session,2020-03-09 12:00:00-04:00,PSTI,neutral
1038818.0,38 Stocks Moving in Monday's Pre-Market Session,2020-03-09 07:19:00-04:00,PSTI,neutral
1038819.0,40 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-03-03 08:10:00-05:00,PSTI,neutral
1038820.0,Plurusten Therapeutics Announces Barda Has Chosen Not To Move Forward With Funding Of Current Proposal; Decision Is Based On Barda's Technical Consideration As Determined By A Technical Evaluation Panel,2020-03-03 07:37:00-05:00,PSTI,positive
1038821.0,30 Stocks Moving in Tuesday's Pre-Market Session,2020-02-18 07:13:00-05:00,PSTI,neutral
1038822.0,76 Biggest Movers From Friday,2020-02-18 05:13:00-05:00,PSTI,neutral
1038823.0,Pluristem Therapeutics CEO Sends Letter To Shareholders,2020-02-10 07:13:00-05:00,PSTI,neutral
1038824.0,68 Biggest Movers From Yesterday,2019-12-18 04:56:00-05:00,PSTI,neutral
1038825.0,Pluristem Completes 75% Enrollment In Its Pivotal Phase III CLI Clinical Study,2019-12-17 07:17:00-05:00,PSTI,neutral
1038826.0,"Benzinga's Top Upgrades, Downgrades For December 16, 2019",2019-12-16 10:10:00-05:00,PSTI,positive
1038827.0,"Dawson James Initiates Coverage On Pluristem Therapeutics with Buy Rating, Announces $12 Price Target",2019-12-16 07:45:00-05:00,PSTI,neutral
1038828.0,19 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-12-03 07:46:00-05:00,PSTI,neutral
1038829.0,Pluristem Completes 50% Enrollment In Phase III PLX-PAD Muscle Injury Study,2019-12-03 07:08:00-05:00,PSTI,negative
1038830.0,9 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-11-29 07:43:00-05:00,PSTI,neutral
1038831.0,24 Stocks Moving in Friday's Pre-Market Session,2019-11-29 07:39:00-05:00,PSTI,neutral
1038832.0,"Pluristem Therapeutics Granted European Patent Number EP2697362 Titled ""Methods And Systems For Harvesting Cells""",2019-11-27 11:23:00-05:00,PSTI,positive
1038833.0,"The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data",2019-11-20 07:25:00-05:00,PSTI,positive
1038834.0,"The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout",2019-11-19 07:56:00-05:00,PSTI,neutral
1038835.0,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",2019-11-14 08:07:00-05:00,PSTI,positive
1038836.0,"The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut",2019-11-08 08:14:00-05:00,PSTI,neutral
1038837.0,Watching Pluristem Shares Following Tweet From Patent Grants Highlighting WIPO PatentScope Application For 'use of specialized vessels for formulating and dispensing pharmaceutical formulations',2019-10-24 09:52:00-04:00,PSTI,positive
1038838.0,21 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-09-27 08:45:00-04:00,PSTI,neutral
1038839.0,33 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-08-19 08:47:00-04:00,PSTI,neutral
1038840.0,"The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission",2019-08-16 07:33:00-04:00,PSTI,negative
1038841.0,"The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings",2019-08-15 07:45:00-04:00,PSTI,neutral
1038842.0,Pluristem 8-K Shows Co. Regained Compliance With Nasdaq Listing Requirement For Minimum Closing Bid Price Above $1/Share,2019-08-12 07:23:00-04:00,PSTI,neutral
1038843.0,70 Biggest Movers From Yesterday,2019-08-06 04:46:00-04:00,PSTI,neutral
1038844.0,45 Stocks Moving In Monday's Mid-Day Session,2019-08-05 12:37:00-04:00,PSTI,neutral
1038845.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-01 09:38:00-04:00,PSTI,neutral
1038846.0,Pluristem And US Department Of Defense Present Data From Studies Testing PLX-R18 As A Prophylactic Treatment For Acute Radiation Syndrome,2019-07-31 08:10:00-04:00,PSTI,positive
1038847.0,54 Biggest Movers From Yesterday,2019-07-30 05:00:00-04:00,PSTI,neutral
1038848.0,42 Stocks Moving In Monday's Mid-Day Session,2019-07-29 12:30:00-04:00,PSTI,neutral
1038849.0,62 Biggest Movers From Friday,2019-07-29 05:47:00-04:00,PSTI,neutral
1038850.0,64 Biggest Movers From Yesterday,2019-07-26 04:36:00-04:00,PSTI,neutral
1038851.0,50 Stocks Moving In Thursday's Mid-Day Session,2019-07-25 13:22:00-04:00,PSTI,neutral
1038852.0,"The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug",2019-07-25 07:21:00-04:00,PSTI,negative
1038853.0,"The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index",2019-07-24 07:08:00-04:00,PSTI,neutral
1038854.0,Pluristem Announces 1:10 Reverse Split of its Common Shares,2019-07-24 03:40:00-04:00,PSTI,positive
1038855.0,Pluristem And U.S. Department Of Defense To Announce Data From Studies Testing PLX-R18 As A Prophylactic Treatment For Acute Radiation Syndrome At RITN,2019-07-17 07:02:00-04:00,PSTI,positive
1038856.0,Pluristem Therapeutics CEO Issues Shareholder Letter,2019-07-02 07:05:00-04:00,PSTI,neutral
1038857.0,Pluristem Therapeutics Announces Yaky Yanay CEO Following Period of Co-CEOs,2019-06-24 07:04:00-04:00,PSTI,neutral
1038858.0,Pluristem Highlights Publication In 'European Journal of Vascular and Endovascular Surgery' Of 'PLX-PAD Cell Treatment of Critical Limb Ischemia: Rationale and Design of the PACE Trial',2019-05-15 07:18:00-04:00,PSTI,negative
1038859.0,"Pluristem Completes Interim Enrollment in Pivotal CLI Study, Targeting Potential Conditional Marketing Approval in Europe",2019-04-29 07:13:00-04:00,PSTI,positive
1038860.0,"Pluristem Therapeutics In Shareholder Letter Says Recent Financing Provides Funding Through Multiple Potentially Value-Creating Milestones; Co. Short And Mid-Term Milestones, Targeting Marketing And Significant Contracts",2019-04-23 08:06:00-04:00,PSTI,positive
1038861.0,"The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership",2019-04-05 07:48:00-04:00,PSTI,positive
1038862.0,52 Biggest Movers From Yesterday,2019-04-05 05:55:00-04:00,PSTI,neutral
1038863.0,44 Stocks Moving In Thursday's Mid-Day Session,2019-04-04 12:39:00-04:00,PSTI,neutral
1038864.0,Mid-Morning Market Update: Markets Open Higher; Constellation Brands Tops Q4 Estimates,2019-04-04 10:08:00-04:00,PSTI,positive
1038865.0,"Pluristem Therapeutics shares are trading lower after the company announced a $20 million offering, comprised of common stock and warrants, priced at $0.70 per share.",2019-04-04 09:45:00-04:00,PSTI,positive
1038866.0,Pluristem Therapeutics Prices ~27.14M Share Offering At $0.70/Share,2019-04-04 09:18:00-04:00,PSTI,positive
1038867.0,32 Stocks Moving In Thursday's Pre-Market Session,2019-04-04 08:18:00-04:00,PSTI,neutral
1038868.0,"The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Droves, Silk Road, NGM Biopharma To Debut",2019-04-04 07:58:00-04:00,PSTI,neutral
1038869.0,Pluristem Therapeutics Reports Proposed Offering Of Common Stock And Warrants,2019-04-03 16:52:00-04:00,PSTI,neutral
1038870.0,"Pluristem Therapeutics 8-K Shows CFO, Treasurer, Secretary Erez Egozi Leaving; Chen Franco-Yehuda Named Replacement",2019-03-18 16:38:00-04:00,PSTI,positive
1038871.0,Pluristem Therapeutics Announces Completion Of 2nd Cohort And DSMB Approval To Enroll Final Cohort In Phase I Hematological Study Of PLX-R18,2019-03-12 08:11:00-04:00,PSTI,positive
1038872.0,Pluristem Therapeutics shares are trading higher after the company announced collaboration with NASA to study Pluristem's cell therapy benefits in space missions.,2019-02-20 08:50:00-05:00,PSTI,positive
1038873.0,Pluristem Enters Into Collaboration With NASA To Study PLX Therapeutic Benefits In Space Missions,2019-02-20 07:31:00-05:00,PSTI,positive
1038874.0,Pluristem To Collaborate With Israeli Ministry Of Defense In The Treatment Of Burn Injuries,2019-01-22 07:01:00-05:00,PSTI,positive
1038875.0,Pluristem Therapeutics Reports Successful One-Year Follow Up Case Study In Treatment Of Buerger's Disease Patient,2019-01-09 08:04:00-05:00,PSTI,positive
1038876.0,Pluristem Concludes Meeting With FDA On Development Plan For Acute Radiation Syndrome,2019-01-03 08:33:00-05:00,PSTI,neutral
1038877.0,"Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018",2018-12-14 11:03:00-05:00,PSTI,negative
1038878.0,"The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen",2018-12-13 07:56:00-05:00,PSTI,positive
1038879.0,"The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel",2018-12-12 08:07:00-05:00,PSTI,positive
1038880.0,"The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings",2018-12-11 08:22:00-05:00,PSTI,neutral
1038881.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018",2018-12-10 11:01:00-05:00,PSTI,negative
1038882.0,"Pluristem Therapeutics Enters Into Cell Thawing Device License Agreement With Chart Industries, Inc.",2018-12-04 07:10:00-05:00,PSTI,positive
1038883.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs",2018-12-02 17:51:00-05:00,PSTI,neutral
1038884.0,"Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018",2018-11-28 11:54:00-05:00,PSTI,negative
1038885.0,Pluristem To Present First Cohort Data From PLX-R18 Hematological Study At American Society Of Hematology's (ASH) Annual Meeting,2018-11-28 08:01:00-05:00,PSTI,neutral
1038886.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018",2018-11-27 11:26:00-05:00,PSTI,negative
1038887.0,Pluristem Therapeutics Gives an Update on its Phase II Study of PLX-PAD,2018-11-12 07:34:00-05:00,PSTI,neutral
1038888.0,"Pluristem Therapeutics Reports $22.5M In Cash, Cash Equivalents At End Of Q1",2018-11-08 08:55:00-05:00,PSTI,neutral
1038889.0,"Pluristem Says Will Present Data From Phase II IC Study At American Heart Association Scientific Sessions Nov. 5-7, 2018",2018-10-18 06:36:00-04:00,PSTI,neutral
1038890.0,U.S. FDA Approves Cost Recovery For Pluristem Therapeutics' PLX-PAD Under Expanded Access Program In Treatment Of Critical Limb Ischemia,2018-10-16 07:01:00-04:00,PSTI,positive
1038891.0,"Stocks Which Set New 52-Week Low Yesterday, October 10th",2018-10-11 09:11:00-04:00,PSTI,negative
1038892.0,"Pluristem Q4 Had $30.6M In Cash, Cash Equivalents, Bank, Restricted Deposits",2018-09-27 07:04:00-04:00,PSTI,negative
1038893.0,Pluristem Therapeutics Earlier Announced FDA ORphan Drug Designation For PLX Cell Therapy In The Treatment Of Graft Failure And Incomplete Recovery Following Hematopietic Cell Transplantation,2018-09-25 08:43:00-04:00,PSTI,negative
1038894.0,"Traders Circulating Word Pluristem's Treatment For Graft Failure, Incomplete Hematopoietic Recovery Received Orphan Drug Designation From FDA; Pluristem Shares Spiked To After-Hours High Of $1.46, Now Up ~3.8% To $1.35",2018-09-24 16:19:00-04:00,PSTI,negative
1038895.0,Pluristem Initiates Two Pivotal Phase III Studies In Israel,2018-08-08 07:03:00-04:00,PSTI,neutral
1038896.0,"Pluristem Therapeutics, Rexahn Pharma Are Biotech Winners, B Riley FBR Says In Bullish Initiation",2018-07-31 15:16:00-04:00,PSTI,positive
1038897.0,"B. Riley FBR Initiates Coverage On Pluristem Therapeutics with Buy Rating, Announces $4.50 Price Target",2018-07-31 08:21:00-04:00,PSTI,neutral
1038898.0,Pluristem Granted Key Patent in Japan for Treatment of GI Following Acute Radiation Exposure,2018-07-26 07:15:00-04:00,PSTI,positive
1038899.0,Pluristem Signs Collaboration Agreement With Thermo Fisher Scientific,2018-07-09 07:00:00-04:00,PSTI,positive
1038900.0,Pluristem and Fukushima University Report 'Positive' Data: PLX-R18 Increases Survival Rates and Mitigates Severe Intestinal Damage after Acute Radiation Exposure,2018-06-25 07:13:00-04:00,PSTI,negative
1038901.0,"UPDATE: Pluristem Says PLX-R18 Cell Therapy Product To Be Funded By US National Institutes Of Health, No Term Disclosed",2018-06-19 07:14:00-04:00,PSTI,negative
1038902.0,Pluristem Therapeutics Reports US Dept. Of Defense To Study Co.'s PLX-R18 For Treatment Of Mustard Gas Injuries,2018-06-19 07:14:00-04:00,PSTI,positive
1038903.0,"U.S. Dept. of Defense to Study Pluristem's PLX-R18 for the Treatment of Mustard Gas Injuries, Study To Be Funded By U.S. NIH; Will Be Second Project For Dept. Of Defense With PLX-R18 Cell Therapy Product",2018-06-19 07:01:00-04:00,PSTI,positive
1038904.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Jun. 12, 2018",2018-06-12 12:31:00-04:00,PSTI,positive
1038905.0,Benzinga Pro's 5 Stocks To Watch Today,2018-06-12 09:23:00-04:00,PSTI,neutral
1038906.0,Pluristem Reports Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study,2018-06-12 06:03:00-04:00,PSTI,positive
1038907.0,"Pluristem Therapeutics Shares Up 2.7%; Co. Earlier Announced Will Release Top-Line Results From Phase II Intermittent Claudication Study On Jun. 12, 2018",2018-06-04 09:53:00-04:00,PSTI,positive
1038908.0,Pluristem Therapeutics In 10-Q Filing Wednesday Afternoon Reported Q3 EPS $(0.01) Beats $(0.09) Estimate,2018-05-10 09:21:00-04:00,PSTI,neutral
1038909.0,36 Biggest Movers From Yesterday,2018-05-01 05:02:00-04:00,PSTI,neutral
1038910.0,FDA Clears New Drug Application For Pluristem's PLX-R18; What's Next?,2018-04-30 14:46:00-04:00,PSTI,positive
1038911.0,36 Stocks Moving In Monday's Mid-Day Session,2018-04-30 13:16:00-04:00,PSTI,neutral
1038912.0,Pluristem Shares Up 7.5% After FDA Cleared Co.'s IND For LX-R18,2018-04-30 12:29:00-04:00,PSTI,positive
1038913.0,"Benzinga Pro's Most-Searched Tickers For Morning Of Mon., Apr. 30, 2018",2018-04-30 10:15:00-04:00,PSTI,neutral
1038914.0,Mid-Morning Market Update: Markets Open Higher; Sprint And T-Mobile To Merge In $26 Billion Deal,2018-04-30 10:06:00-04:00,PSTI,neutral
1038915.0,Benzinga Pro's 6 Stocks To Watch Today,2018-04-30 08:41:00-04:00,PSTI,neutral
1038916.0,U.S. FDA Clears Pluristem's IND for PLX-R18 to Treat Victims Exposed to Acute Radiation,2018-04-30 07:05:00-04:00,PSTI,positive
1038917.0,Benzinga Pro's 5 Stocks To Watch Today,2018-04-25 08:46:00-04:00,PSTI,neutral
1038918.0,US FDA Clears Pluristem's Phase III Study in Treatment of Muscle Injury Following Hip Fracture Surgery,2018-04-25 07:06:00-04:00,PSTI,negative
1038919.0,"Pluristem and Indiana University to Initiate Joint Project Evaluating PLX-R18 in Acute Radiation Syndrome, Targeting Bridging Data for Pivotal Study",2018-04-23 07:01:00-04:00,PSTI,neutral
1038920.0,Pluristem Therapeutics Shares Up 13% Premarket Tues. After FDA Cleared Expanded Access Program To Initiate Treatments of Critical Limb Ischemia,2018-01-09 08:57:00-05:00,PSTI,positive
1038921.0,"FDA Clears Pluristem's Expanded Access Program to Initiate Treatments of Critical Limb Ischemia Outside of Ongoing Phase III Study, FDA May Also Allow Pluristem to Be Compensated for the Cost of Treatment",2018-01-09 07:04:00-05:00,PSTI,neutral
1038922.0,Pluristem Reports $8.7M Grant Key US Patent For Skeletal Muscle Regeneration,2017-11-22 07:08:00-05:00,PSTI,positive
1038923.0,Pluristem Reports Deal With Tel Aviv Sourasky Medical Center To Conduct Phase I/II Trial In Steroid-Refractory Chronic GvHD,2017-11-06 07:17:00-05:00,PSTI,neutral
1038924.0,40 Biggest Movers From Yesterday,2017-10-31 04:54:00-04:00,PSTI,neutral
1038925.0,"UPDATE: Pluristem 9M Share Offering Is On THe Tel Aviv Stock Exchange, Co. Expects Gross Proceeds Of $15.1M",2017-10-30 14:46:00-04:00,PSTI,negative
1038926.0,Pluristem Reports Offering Of 9M Shares At $1.67/Share,2017-10-30 14:45:00-04:00,PSTI,positive
1038927.0,35 Stocks Moving In Monday's Mid-Day Session,2017-10-30 12:30:00-04:00,PSTI,neutral
1038928.0,Mid-Morning Market Update: Markets Mostly Lower; Lennar To Buy CalAtlantic,2017-10-30 09:58:00-04:00,PSTI,negative
1038929.0,Pluristem Proposes to Launch Up to 9M Share Public Offering of Common Stock on the Tel Aviv Stock Exchange After Concluding Israeli Institutional Investors Tender,2017-10-29 18:55:00-04:00,PSTI,positive
1038930.0,32 Stocks Moving In Monday's Mid-Day Session,2017-10-23 12:31:00-04:00,PSTI,neutral
1038931.0,25 Stocks Moving In Monday's Pre-Market Session,2017-10-23 08:03:00-04:00,PSTI,neutral
1038932.0,Pluristem Announces a European Patent for RLX-R18,2017-10-23 07:06:00-04:00,PSTI,neutral
1038933.0,Pluristem Therapeutics Reports FDA Orphan Drug Designation For PLX-R18 Cell Therapy As Treatment For Acute Radiation Syndrome,2017-10-19 07:37:00-04:00,PSTI,neutral
1038934.0,"Seaport Global Initiates Coverage On Pluristem Therapeutics with Buy Rating, Announces $5.00 Price Target",2017-10-06 09:55:00-04:00,PSTI,neutral
1038935.0,"Pluristem Receives 'Positive' Feedback from FDA and EMA as Company Prepares for Phase III Trial of PLX-PAD to Support Recovery from Hip Fracture, Trial Awarded $8.7M Grant",2017-09-26 07:04:00-04:00,PSTI,positive
1038936.0,12 Biggest Mid-Day Gainers For Monday,2017-09-18 12:29:00-04:00,PSTI,neutral
1038937.0,22 Stocks Moving In Monday's Pre-Market Session,2017-09-18 08:07:00-04:00,PSTI,neutral
1038938.0,A Peek Into The Markets: U.S. Stock Futures Signal Higher Start On Wall Street,2017-09-18 07:35:00-04:00,PSTI,neutral
1038939.0,Pluristem Therapeutics Granted FDA Fast Track Designation for PLX-PAD,2017-09-18 07:00:00-04:00,PSTI,positive
1038940.0,Pluristem Granted Two Hong Kong Patents for Critical Limb Ischemia and Muscle Regeneration,2017-09-13 07:08:00-04:00,PSTI,negative
1038941.0,Pluristem Therapeutics Awarded $8.7 Million to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program,2017-09-05 07:07:00-04:00,PSTI,positive
1038942.0,Pluristem Therapeutics Announces Pilot Study Of PLX-R18 Cell Therapy Will Be Initiated By U.S. Dept. Of Defense's Armed Forces Radiobiology Research Institute,2017-08-16 07:32:00-04:00,PSTI,neutral
1038943.0,"Pluristem Therapeutics Says ARS Study Show Hematological Deficiencies Even At Low Radiation Levels, Believes This Could Pave Way For Potential Use Of PLX-R18 To Support Hematological Recovery Following Radiotherapy, Chemotherapy",2017-07-26 13:04:00-04:00,PSTI,positive
1038944.0,8-K From Pluristem Shows Co. Entered AT Market Issuance Sales Deal For Up To $80M In Common Stock,2017-07-07 08:45:00-04:00,PSTI,neutral
1038945.0,Maxim Group Upgrades Pluristem Therapeutics to Buy; Stock Up 6.6% For Session,2017-06-19 15:34:00-04:00,PSTI,neutral
1038946.0,Pluristem Says PLX-R18 Was Effective in Increasing Survival Rates,2017-05-22 07:36:00-04:00,PSTI,positive
1038947.0,UPDATE: Pluristem Announces All PLX-Treated Groups Showed Improvements in Survival Rates vs Untreated Groups,2017-05-03 07:28:00-04:00,PSTI,positive
1038948.0,Pluristem Therapeutics Reports Results from Non-Human Primate Pilot Study of PLX-R18 in Acute Radiation Syndrome,2017-05-03 07:28:00-04:00,PSTI,neutral
1038949.0,Pluristem Announces Promising Results from Non-Human Primate Pilot Study of PLX-R18 in Acute Radiation Syndrome,2017-05-03 07:13:00-04:00,PSTI,positive
1038950.0,Pluristem Therapeutics Reports Hit 100 Granted Patents Milestone,2017-04-19 08:01:00-04:00,PSTI,positive
1038951.0,Pluristem And Sosei Advance Toward Finalizing Joint Venture For Commercialization Of PLX-PAD In Japan,2017-03-30 16:01:00-04:00,PSTI,neutral
1038952.0,Pluristem Reports Co. Sosei CVC Are Advancing Toward JV for Commercialization of PLX-PAD in Japan,2017-03-30 16:01:00-04:00,PSTI,neutral
1038953.0,"Pluristem Therapeutics Launches Co-CEO Structure, Appoints Erez Egozi CFO",2017-03-29 16:00:00-04:00,PSTI,neutral
1038954.0,"Pluristem Says Phase 3 CLI Trial To Commence In U.S. and EU In 1H 2017, Also Expects TO Begin Enrollment In PLX-R18 In Q1",2017-02-13 07:11:00-05:00,PSTI,neutral
1038955.0,Mid-Afternoon Market Update: Skyworks Surges After Strong Earnings Report; Affimed Shares Drop,2017-01-20 14:38:00-05:00,PSTI,positive
1038956.0,15 Biggest Mid-Day Losers For Friday,2017-01-20 13:01:00-05:00,PSTI,negative
1038957.0,Mid-Day Market Update: Crude Oil Up 2.8%; Bristol-Myers Squibb Shares Slide After Opdivo Decision,2017-01-20 12:04:00-05:00,PSTI,negative
1038958.0,Mid-Morning Market Update: Markets Open Higher; General Electric Revenue Misses Views,2017-01-20 09:55:00-05:00,PSTI,negative
1038959.0,Pluristem Incrases Bought Deal to $15M of Stock and Warrants,2017-01-20 07:00:00-05:00,PSTI,neutral
1038960.0,Pluristem Reports Bought-Deal Offering of ~8.16M Shares at $1.225/Share,2017-01-19 16:54:00-05:00,PSTI,positive
1038961.0,Pluristem Receives Clearance from Germany to Initiate Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval,2017-01-17 06:10:00-05:00,PSTI,positive
1038962.0,Pluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval[+] GLN,2017-01-17 06:01:00-05:00,PSTI,negative
1038963.0,Pluristem Phase 3 Study Cleared by FDA,2017-01-10 07:02:00-05:00,PSTI,positive
1038964.0,"Pluristem, New York Blood Center to Collaborate in Evaluating PLX-R18 as an Adjuvant Therapy to Umbilical Cord Blood Transplantation, Winning $900K Funding from BIRD",2016-12-27 04:06:00-05:00,PSTI,positive
1038965.0,"Pluristem, Sosei CVC to Establish a New Corporation for Commercialization of PLX-PAD in Japan",2016-12-20 04:24:00-05:00,PSTI,neutral
1038966.0,"Pluristem Therapeutics Reports $30M Equity Investment Term Sheet Signed with Large Chinese Investment Fund; Reports $29.3M in Cash, Cash Equivalents as of Sept. 30, 2016",2016-11-15 07:08:00-05:00,PSTI,neutral
1038967.0,Pluristem Phase 3 Trials Approved in UK,2016-11-01 07:35:00-04:00,PSTI,positive
1038968.0,"Pluristem +9.2% Premarket @$1.66; Co Signs Term Sheet for $30M Equity Investment Deal with Innovative Medical, Shares Priced at $1.77",2016-10-25 06:52:00-04:00,PSTI,positive
1038969.0,"Pluristem Reports Signing of Term Sheet for $30M Equity Investment Deal with Innovative Medical, Shares Will Be Sold at $1.77",2016-10-25 06:43:00-04:00,PSTI,positive
1038970.0,Pluristem Gives FY16 Corp. Guidance,2016-09-12 07:46:00-04:00,PSTI,neutral
1038971.0,Pluristem's Phase III Critical Limb Ischemia Study Wins $8 Million Grant from Europe's Horizon 2020 Program,2016-08-09 07:19:00-04:00,PSTI,positive
1038972.0,"Pluristem Receives Positive Feedback from FDA and Gears Up for Phase III Trial of PLX-PAD in Critical Limb Ischemia, Primary Endpoint For BLA Will Be Time To Amputation & Death",2016-08-02 07:33:00-04:00,PSTI,negative
1038973.0,"H.C. Wainwright Assumes Pluristem Therapeutics at Buy, Announces $3.50 PT",2016-07-19 07:05:00-04:00,PSTI,neutral
1038974.0,Pluristem Advances Phase I Study Of PLX-R18 Cells To Treat Insufficient Hematologic,2016-07-11 09:02:00-04:00,PSTI,positive
1038975.0,10 Biggest Mid-Day Gainers For Wednesday,2016-06-22 12:39:00-04:00,PSTI,neutral
1038976.0,Pluristem Reports Data Showing PLX-PAD Cells Effective in Treating DMD,2016-06-22 04:10:00-04:00,PSTI,positive
1038977.0,Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial; Data release on track for 2017,2016-05-16 04:02:00-04:00,PSTI,neutral
1038978.0,Pluristem Announces $3.3M Grant by Israeli Government,2016-05-09 05:01:00-04:00,PSTI,positive
1038979.0,Pluristem Enters into Licensing Agreement with TES Holdings  to Obtain Key Patent in Japan to Cover Treatment of Ischemic Diseases with Placental Cell Therapy,2016-04-21 04:02:00-04:00,PSTI,positive
1038980.0,Pluristem Therapeutics Announces Receipt Of 2 Key Cell Therapy Patents In Japan; Shares Tick Higher,2016-04-13 08:51:00-04:00,PSTI,positive
1038981.0,Pluristem Granted Two Key Cell Therapy Patents in Japan,2016-04-13 04:16:00-04:00,PSTI,positive
1038982.0,"President Yanay Buys 15,000 Shares of Pluristem Therapeutics @$0.95/Share -Form 4",2016-02-17 16:08:00-05:00,PSTI,positive
1038983.0,Option Alert: PSTI Feb16 1.0 Calls Sweep: 500 @  ASK  $0.25: 500 traded vs 30 OI: $1.16 Ref,2016-02-17 09:33:00-05:00,PSTI,positive
1038984.0,"Chairman Aberman Buys 31,000 Shares of Pluristem Therapeutics @$0.80/Share -Form 4",2016-02-16 16:14:00-05:00,PSTI,positive
1038985.0,Pluristem Receives FDA Clearance to Initiate Clinical Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery Following Bone Marrow Transplant,2016-01-12 04:18:00-05:00,PSTI,positive
1038986.0,Pluristem Therapeutics Announces Publication of Scientific Study of PLX Cells in 'Clinical Science',2016-01-06 05:49:00-05:00,PSTI,neutral
1038987.0,Shares Of Pluristem Therapeutics Surging Following Receipt Of Orphan Drug Designation,2015-12-31 10:20:00-05:00,PSTI,positive
1038988.0,Benzinga's Top #PreMarket Gainers,2015-12-31 08:06:00-05:00,PSTI,positive
1038989.0,Pluristem +31.31% Premarket @$1.30; FDA Granting Orphan Drug Designation to Pluristem's PLX-PAD,2015-12-31 07:08:00-05:00,PSTI,positive
1038990.0,UPDATE: PLX Cells Were Demonstrated to be Safe for Both the Mother and Fetus and Improved Several Parameters of Preeclampsia in Several Animal Studies,2015-12-31 07:00:00-05:00,PSTI,positive
1038991.0,U.S. Food & Drug Administration Grants Orphan Drug Designation to Pluristem's PLX-PAD Cells for Treatment of Severe Preeclampsia,2015-12-31 07:00:00-05:00,PSTI,negative
1038992.0,Pluristem Announces Agreement With Japan's PMDA on Design of Final Trial Needed to Apply for Conditional Approval of PLX-PAD,2015-12-21 04:21:00-05:00,PSTI,positive
1038993.0,"Pluristem COO to Present at Phacilitate Cell & Gene Therapy World Conference in Washington DC on January 25-26, 2016",2015-12-17 04:10:00-05:00,PSTI,neutral
1038994.0,"Pluristem, United Therapeutics End Licensing Agreement; Report Positive Data in Pulmonary Arterial Hypertension",2015-12-08 09:35:00-05:00,PSTI,positive
1038995.0,Pluristem Announces MOU to Collaborate With Fukushima Medical University to Study PLX-R18 in Acute Radiation Syndrome,2015-12-03 04:18:00-05:00,PSTI,neutral
1038996.0,Stocks Hitting 52-Week Lows,2015-11-25 10:13:00-05:00,PSTI,negative
1038997.0,Pluristem to Present New Data on PLX-R18 at ASH Annual Meeting,2015-11-17 04:17:00-05:00,PSTI,neutral
1038998.0,Pluristem Therapeutics Announces Expansion of Coop Deal with Charite for Inclusion of Orthopedic Indications,2015-10-12 07:06:00-04:00,PSTI,neutral
1038999.0,"Pluristem Therapeutics President  Yanay Buys 10,000 Shares @$2.11/Share -Form 4",2015-09-21 16:13:00-04:00,PSTI,positive
1039000.0,"Pluristem, NIAID Met With FDA and Agreed on Development Plan for Initiation of Pivotal Study of PLX-R18 in Treatment of ARS",2015-09-21 05:18:00-04:00,PSTI,positive
1039001.0,"Pluristem Therapeutics President Yanay Buys 10,000 Shares @$2.12/Share -Form 4",2015-09-17 09:29:00-04:00,PSTI,positive
1039002.0,"Pluristem Therapeutics Chairman Aberman Buys 25,000 Shares @$2.11/Share -Form 4",2015-09-16 16:37:00-04:00,PSTI,positive
1039003.0,Pluristem Completed Successful Meeting With FDA in Preparation for Filing an IND for PLX-R18,2015-09-09 04:18:00-04:00,PSTI,positive
1039004.0,Pluristem Issued U.S. Patent 'Adherent Cells From Placenta Tissue and Use Thereof in Therapy',2015-08-17 04:04:00-04:00,PSTI,neutral
1039005.0,Japan's PMDA Grants Safety Clearance to Pluristem's PLX-PAD Cells for Use in Clinical Trials,2015-08-12 04:16:00-04:00,PSTI,positive
1039006.0,Pluristem Announces Key Discussions With Europe's Adaptive Pathways Group on Phase II Protocol in CLI,2015-08-10 04:17:00-04:00,PSTI,neutral
1039007.0,Scientific Study Published in 'Stem Cells' Show Pluristem's PLX Cells Regulate the Immune System,2015-07-27 04:15:00-04:00,PSTI,positive
1039008.0,"UPDATE: Pluristem Therapeutics Prices Offering Of 4.08M Stock At $2.50/Share, Warrants At $2.85 Exercise Price",2015-06-25 09:23:00-04:00,PSTI,neutral
1039009.0,"Pluristem Reports Pricing of Registered Direct Offering of Common Stock, Warrants: 4.08M Shares at Combined Price $2.50/Share",2015-06-25 09:22:00-04:00,PSTI,positive
1039010.0,Pluristem Granted Australian Patent Titled 'Adherent Cells From Placenta Tissue and Use Thereof in Therapy',2015-06-24 04:17:00-04:00,PSTI,positive
1039011.0,Pluristem Announces $2.9M Grant by Israeli Government,2015-06-17 04:07:00-04:00,PSTI,positive
1039012.0,Pluristem Announces Smart Money Grant from Israel's Ministry of Economy for Marketing PLX Cell Therapy in Japan,2015-06-03 04:17:00-04:00,PSTI,positive
1039013.0,"Pluristem Granted Key Cell Patents in Asia, Russia, Mexico, Israel",2015-06-01 04:10:00-04:00,PSTI,positive
1039014.0,"Pluristem Updates Shareholders on Progress of PLX-PAD, PLX-R18",2015-05-25 07:20:00-04:00,PSTI,positive
1039015.0,US Stock Futures Edge Lower Ahead Of Housing Market Index,2015-05-18 07:11:00-04:00,PSTI,negative
1039016.0,Pluristem's PLX Cell Program in Critical Limb Ischemia Selected for EMA's Adaptive Pathways Pilot Project,2015-05-18 04:29:00-04:00,PSTI,negative
1039017.0,Pluristem Announces European Patent for Use of Cells to Help Treat Damaged Bone Marrow,2015-05-06 04:31:00-04:00,PSTI,positive
1039018.0,Pluristem's Clinical Advisory Board Outlines Phase II Clinical Trials in Critical Limb Ischemia,2015-04-20 04:37:00-04:00,PSTI,negative
1039019.0,Pluristem Announces Development Strategy for PLX-R18,2015-03-24 04:36:00-04:00,PSTI,neutral
1039020.0,"Pluristem to Present Data at Regenerative Medicine Conferences in Japan, S Korea",2015-03-09 04:31:00-04:00,PSTI,neutral
1039021.0,Pluristem Therapeutics Reports Positive Results From Evaluation Of PLX-R18 Cells,2015-02-19 12:49:00-05:00,PSTI,positive
1039022.0,Pluristem Announces Significant Findings in US NIH Trial of PLX-R18 Cells for Treatment of Acute Radiation Syndrome,2015-02-18 04:30:00-05:00,PSTI,positive
1039023.0,Mid-Day Market Update: U.S. Stocks Turn Higher; Tenneco Shares Rise On Upbeat Earnings,2015-02-02 12:23:00-05:00,PSTI,positive
1039024.0,Morning Market Losers,2015-02-02 09:56:00-05:00,PSTI,negative
1039025.0,Pluristem Announces Significant New Finding from Phase I/II Muscle Injury Trial,2015-02-02 04:55:00-05:00,PSTI,negative
1039026.0,Pluristem Shares Rises 17%; Presenting at Cell & Gene Therapy Forum 2015 in Washington DC,2015-01-28 09:51:00-05:00,PSTI,positive
1039027.0,What Investors Are Looking At In The Stem Cell Sector,2015-01-13 11:48:00-05:00,PSTI,neutral
1039028.0,Pluristem CEO Issues Letter to Shareholders,2015-01-12 04:28:00-05:00,PSTI,neutral
1039029.0,Pluristem Awarded Patent for Foundational Cell Harvesting Technology in South Africa,2015-01-06 04:56:00-05:00,PSTI,positive
1039030.0,What Investors Are Looking For In Brainstorm Cell Therapeutics' Upcoming Clinical Results,2014-12-31 16:02:00-05:00,PSTI,neutral
1039031.0,Pluristem Announces Study Shows PLX Cells Protect Neurons,2014-12-22 04:57:00-05:00,PSTI,positive
1039032.0,"Pluristem, Hadassah Medical Center Annnunce Collaboration",2014-12-04 04:59:00-05:00,PSTI,neutral
1039033.0,Pluristem Announces Patent in Singapore for 3D Cell Expansion Technology,2014-12-01 04:57:00-05:00,PSTI,neutral
1039034.0,US Stock Futures Slide Ahead Of Macy's Earnings,2014-11-12 07:03:00-05:00,PSTI,neutral
1039035.0,"Pluristem Granted Patent in Australia, New Zealand for Use of Placental Cells in Treatment of Multiple Indications",2014-11-12 05:01:00-05:00,PSTI,positive
1039036.0,Case Western to Pre-Clinical Study of Pluristem's PLX-RAD Cells ,2014-10-27 04:58:00-04:00,PSTI,neutral
1039037.0,Pluristem Completes Development of Second Major Cell Therapy Product Line ,2014-10-21 05:02:00-04:00,PSTI,neutral
1039038.0,S-3 Filing from Pluristem Therapeutics Shows Registration for $200M Mixed Securities Shelf Offering,2014-10-14 16:43:00-04:00,PSTI,positive
1039039.0,US Stock Futures Drop Ahead Of Consumer Credit Data,2014-10-07 07:05:00-04:00,PSTI,positive
1039040.0,Pluristem Wins Cell Therapy Patent Case in Europe,2014-10-07 05:19:00-04:00,PSTI,positive
1039041.0,"Pluristem Therapeutics Charman Aberman Buys 5,000 Shares @$2.92/Share -Form 4",2014-09-23 10:55:00-04:00,PSTI,positive
1039042.0,"Pluristem Therapeutics Chairman Aberman Buys 15,000 Shares @$2.84/Share -Form 4",2014-09-17 16:09:00-04:00,PSTI,positive
1039043.0,Pluristem Evaluating Strategic Opportunities in Japan ,2014-09-16 05:22:00-04:00,PSTI,positive
1039044.0,8-K from Pluristem Therapeutics Shows Co. Gave Notice to MLV of Terminated Sales Deal ,2014-09-11 16:30:00-04:00,PSTI,neutral
1039045.0,United Therapeutics Advances to Second Cohort in Phase I Trial of Pluristem's PLX-PAD Cells for Treatment of PAH,2014-09-08 05:16:00-04:00,PSTI,positive
1039046.0,Pluristem Initiates South Korean Sites in Phase II Intermittent Claudication Trial ,2014-07-08 05:25:00-04:00,PSTI,neutral
1039047.0,Pluristem Selects Rotator Cuff Repair as Second Indication in Orthopedic Clinical Program,2014-06-25 05:32:00-04:00,PSTI,neutral
1039048.0,Pluristem AwardedPatent in Russia for Treatment of Inflammatory Bowel Disease Using Placenta-Derived Cells ,2014-06-19 05:24:00-04:00,PSTI,neutral
1039049.0,Pluristem Granted Patent in India for Cell Therapy Production Methods and Compositions ,2014-06-16 05:33:00-04:00,PSTI,positive
1039050.0,Pluristem Updates Shareholders ,2014-06-05 05:27:00-04:00,PSTI,neutral
1039051.0,Pluristem Announces Enhanced Activity in Orthopedic Indications for PLX Cell Therapies,2014-05-29 05:31:00-04:00,PSTI,neutral
1039052.0,Pluristem Receives Clearance from South Korean MFDS to Use PLX Cells Manufactured at Haifa Facility  ,2014-05-20 05:30:00-04:00,PSTI,neutral
1039053.0,Pluristem to be Added to New TA Tech-Elite Stock Index on Tel Aviv Stock Exchange,2014-05-07 05:29:00-04:00,PSTI,neutral
1039054.0,Pluristem's Manufacturing Facility Receives EU Approval,2014-04-28 05:36:00-04:00,PSTI,positive
1039055.0,Pluristem to Present at ISCT 2014 ,2014-04-16 05:43:00-04:00,PSTI,neutral
1039056.0,"Pluristem to Present Poster on GvHD, Participate in Panel Discussion at BIRAX ",2014-03-25 05:38:00-04:00,PSTI,neutral
1039057.0,Pluristem Presents Promising Preliminary Results for PLX-PAD Cells in Tendon Injury at AAOS Annual Meeting ,2014-03-12 05:40:00-04:00,PSTI,neutral
1039058.0,"Morning Gainers for Mar. 6, 2014: PXLW, SGMO, ERII, RGSE, NAVB, PSTI",2014-03-06 11:08:00-05:00,PSTI,neutral
1039059.0,Pluristem Gets FDA Approval for Commercial Scale Cell Manufacturing Process ,2014-03-06 05:38:00-05:00,PSTI,positive
1039060.0,Pluristem Submits Orphan Drug Application to  FDA for Preeclampsia ,2014-02-20 05:37:00-05:00,PSTI,neutral
1039061.0,Pluristem Awarded 3D Cell Expansion Patent in Australia ,2014-02-18 05:44:00-05:00,PSTI,positive
1039062.0,Pluristem Announces Yaky Yanay Named President and CEO,2014-02-05 05:42:00-05:00,PSTI,neutral
1039063.0,US NIH to Commence Study of Pluristem's PLX Cells for ARS,2014-02-03 05:41:00-05:00,PSTI,neutral
1039064.0,Pluristem CEO Issues Letter to Shareholders ,2014-01-30 05:39:00-05:00,PSTI,neutral
1039065.0,Pluristem Receives German Regulatory Approval of New Scaled-Up 3D Manufacturing Process,2014-01-23 06:55:00-05:00,PSTI,positive
1039066.0,UPDATE: Pluristem Shares Rise 6% Pre-Market on  Phase I/II Muscle Injury Trial Meeting Primary Safety & Efficacy Endpoints ,2014-01-21 07:55:00-05:00,PSTI,positive
1039067.0,Pluristem's Phase I/II Muscle Injury Trial Meets Primary Safety & Efficacy Endpoints ,2014-01-21 05:41:00-05:00,PSTI,neutral
1039068.0,"Option Alert; Pluristem June $6 Call; 2,045 Contracts Traded Wednesday vs 5 Open Interest",2014-01-08 12:01:00-05:00,PSTI,positive
1039069.0,"US Stock Futures Edge Lower Ahead Of ADP Report, FOMC Minutes",2014-01-08 07:16:00-05:00,PSTI,negative
1039070.0,Pluristem Awarded Placental Cell Therapy Patent in Australia ,2014-01-08 05:44:00-05:00,PSTI,positive
1039071.0,"Pluristem's Phase I/II Muscle Injury Trial Results to be Announced on January 21, 2014 ",2014-01-06 05:45:00-05:00,PSTI,negative
1039072.0,US Stock Futures Flat Ahead Of Fed,2013-12-17 07:11:00-05:00,PSTI,neutral
1039073.0,Pluristem Issues 2.5M Shares in Exchange for 1.011M Shares of CHA,2013-12-17 05:44:00-05:00,PSTI,positive
1039074.0,Pluristem Receives Regulatory Korean Approval to Extend Phase II Study of PLX-PAD Cells for Treatment of IC,2013-11-13 06:08:00-05:00,PSTI,positive
1039075.0,Pluristem Announces Safety of PLX Cells in Pre-Clinical Pregnancy Model ,2013-11-04 05:47:00-05:00,PSTI,positive
1039076.0,Pluristem to Present at Stem Cell Meeting on the Mesa ,2013-10-15 05:57:00-04:00,PSTI,neutral
1039077.0,Pluristem Receives Israeli Ministry of Health Approval to Initiate Phase II Study Using PLacental eXpanded,2013-10-02 05:49:00-04:00,PSTI,positive
1039078.0,Pluristem's PLX Cells Demonstrate Efficacy in Preliminary Animal Experiment for Graft vs Host Disease ,2013-10-01 06:01:00-04:00,PSTI,neutral
1039079.0,"Maxim Group Upgrades Pluristem Therapeutics, Inc. to Buy",2013-09-16 10:17:00-04:00,PSTI,neutral
1039080.0,FDA Lifts Clinical Hold on Pluristem's Phase II Intermittent Claudication Study ,2013-09-16 05:33:00-04:00,PSTI,neutral
1039081.0,US Stock Futures Flat; Apple Shares Drop In Pre-Market Trading,2013-09-11 07:07:00-04:00,PSTI,neutral
1039082.0,Pluristem Awarded US Patent for Treatment of Peripheral Artery Disease ,2013-09-11 05:42:00-04:00,PSTI,positive
1039083.0,Pluristem's PLX Cells Demonstrate Favorable Properties in Treatment of Tendon Injuries,2013-08-14 05:58:00-04:00,PSTI,positive
1039084.0,Pluristem Awarded $3.3 M Israeli Government Grant,2013-08-06 05:44:00-04:00,PSTI,positive
1039085.0,NIAID Recommends to Expand Scope of Research in Development of Pluristem's PLX-RAD Cells,2013-07-18 06:25:00-04:00,PSTI,positive
1039086.0,Pluristem Announces Completion of Enrollment for Phase I/II Muscle Injury Trial ,2013-07-11 05:55:00-04:00,PSTI,negative
1039087.0,Pluristem Announces South Korean Partner Files IND With Korean FDA ,2013-07-08 05:58:00-04:00,PSTI,neutral
1039088.0,A Peek Into The Market Before The Trading Starts,2013-06-26 07:18:00-04:00,PSTI,neutral
1039089.0,"Pluristem, Cha Bio&Diostech Enter Into Strategic Partnership and Licensing Agreement in South Korea",2013-06-26 06:02:00-04:00,PSTI,positive
1039090.0,A Peek Into The Market Before The Trading Starts,2013-06-20 07:15:00-04:00,PSTI,neutral
1039091.0,Pluristem's Preclinical Results for PLX-RAD Cells Published in PLOS ONE ,2013-06-20 06:05:00-04:00,PSTI,neutral
1039092.0,Pluristem Issues Update on Clinical Status of IC Trials,2013-06-19 09:01:00-04:00,PSTI,neutral
1039093.0,"Pluristem Issues Responses from CEO Aberman in Q&A, Says No Effect on PLX-PAD Other Trials Outside US",2013-06-06 10:33:00-04:00,PSTI,negative
1039094.0,UPDATE: Jefferies Lowers PT on Pluristem Therapeutics Following Phase 2 Trial Suspension,2013-06-05 11:42:00-04:00,PSTI,negative
1039095.0,Maxim Says Clinical Hold for Pluristem Means All Trials Delayed,2013-06-05 08:54:00-04:00,PSTI,negative
1039096.0,"Jefferies Maintains Hold on Pluristem Therapeutics, Inc., Lowers PT to $3.00",2013-06-05 07:27:00-04:00,PSTI,negative
1039097.0,"Maxim Group Downgrades Pluristem Therapeutics, Inc. to Hold",2013-06-04 13:07:00-04:00,PSTI,neutral
1039098.0,Morning Market Losers,2013-06-04 10:18:00-04:00,PSTI,negative
1039099.0,"Shares of Pluristem Therapeutics Resume Trade, Down 14-16%",2013-06-04 09:50:00-04:00,PSTI,positive
1039100.0,Shares of Pluristem Therapeutics to Resume Trade at 9:50AM EDT,2013-06-04 09:08:00-04:00,PSTI,positive
1039101.0,UPDATE: Pluristem to Receive Clinical-hold Notice From the U.S. FDA,2013-06-04 09:02:00-04:00,PSTI,neutral
1039102.0,"Pluristem Announces Clinical-Hold Notice from US FDA for Phase III IC Study IND 15038, Cites 'Serious Allergic Reaction'",2013-06-04 09:01:00-04:00,PSTI,negative
1039103.0,Pluristem Therapeutics Halted News Pending,2013-06-04 08:57:00-04:00,PSTI,neutral
1039104.0,UPDATE: MLV Initiates Pluristem Therapeutics at Buy on Unique Cell Therapy Platform,2013-05-31 08:44:00-04:00,PSTI,neutral
1039105.0,"McNicoll Lewis Vlak Initiates Coverage on Pluristem Therapeutics, Inc. at Buy, Announces $4.50 PT",2013-05-31 08:22:00-04:00,PSTI,neutral
1039106.0,Scientists Create Human Stem Cells By Cloning –Reuters,2013-05-15 12:05:00-04:00,PSTI,positive
1039107.0,Pluristem Announces Preclinical Research Shows PLX Cells May be Effective in Treating Preeclampsia ,2013-05-13 05:57:00-04:00,PSTI,positive
1039108.0,"Pluristem Therapeutics, Inc. Reports Q1 EPS of $(0.10) vs $(0.09) Est; Revenue of $194.0K vs $230.0K Est",2013-05-08 16:51:00-04:00,PSTI,neutral
1039109.0,A Peek Into The Market Before The Trading Starts,2013-05-07 07:19:00-04:00,PSTI,neutral
1039110.0,Pluristem Announces First Clinical Indication for PLX-RAD Cells for Use in Hematology ,2013-05-07 05:54:00-04:00,PSTI,neutral
1039111.0,United Therapeutics Receives Regulatory Approval to Commence Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension ,2013-04-11 06:00:00-04:00,PSTI,positive
1039112.0,A Peek Into The Market Before The Trading Starts,2013-03-20 07:35:00-04:00,PSTI,neutral
1039113.0,Pluristem Provides Update on Phase I/II Clinical Trial for the Treatment of Muscle Injury ,2013-03-20 05:59:00-04:00,PSTI,negative
1039114.0,Benzinga's Top Initiations,2013-03-19 07:58:00-04:00,PSTI,positive
1039115.0,UPDATE: Jefferies Initiates Pluristem Therapeutics at Hold on Balanced Risk/Reward,2013-03-19 07:27:00-04:00,PSTI,neutral
1039116.0,"Jefferies Initiates Coverage on Pluristem Therapeutics, Inc. at Hold, Announces $3.50 PT",2013-03-19 06:20:00-04:00,PSTI,neutral
1039117.0,Pluristem Says United Therapeutics to Begin Phase 1 Trial of PLX-PAD Cells for PAH,2013-02-26 09:04:00-05:00,PSTI,positive
1039118.0,Bloomberg Reporting Pluristem Gets FDA Orphan Drug Status for Aplastic Anemia Treatment,2013-02-20 14:03:00-05:00,PSTI,neutral
1039119.0,Pluristem Moving Into New State-of-the-Art GMP Facility ,2013-01-30 05:57:00-05:00,PSTI,neutral
1039120.0,"Top Narrow Based Indexes For January 15, 2013",2013-01-15 10:47:00-05:00,PSTI,positive
1039121.0,A Peek Into The Market Before The Trading Starts,2013-01-15 07:17:00-05:00,PSTI,neutral
1039122.0,Pluristem Receives Approval to Initiate Phase II Study Using PLX-PAD Cells in Germany ,2013-01-15 06:15:00-05:00,PSTI,positive
1039123.0,Pluristem CEO Sends Letter to Shareholders ,2013-01-07 07:10:00-05:00,PSTI,neutral
1039124.0,A Peek Into The Market Before The Trading Starts,2012-12-27 07:10:00-05:00,PSTI,neutral
1039125.0,Pluristem Initiates Final Validation Steps for New Manufacturing Facility ,2012-12-27 06:15:00-05:00,PSTI,neutral
1039126.0,Pluristem Therapeutics Enters Sales Pact for Up to $95M in Common Stock,2012-12-26 17:30:00-05:00,PSTI,neutral
1039127.0,A Peek Into The Market Before The Trading Starts,2012-11-21 07:19:00-05:00,PSTI,neutral
1039128.0,FDA Updates Pluristem on its Orphan Drug Application for Aplastic Anemia ,2012-11-21 06:20:00-05:00,PSTI,neutral
1039129.0,Pluristem to Initiate Phase I/II  Muscle Injury  Clinical Trial ,2012-11-14 07:27:00-05:00,PSTI,negative
1039130.0,Pluristem Requests Bloomberg Publish Corrections to Article,2012-11-08 21:31:00-05:00,PSTI,neutral
1039131.0,A Peek Into The Market Before The Trading Starts,2012-10-23 07:28:00-04:00,PSTI,neutral
1039132.0,Pluristem Announces Milestone in Build-Out of Its New GMP Manufacturing Facility for Commercial Production of PLX Cells ,2012-10-23 06:18:00-04:00,PSTI,neutral
1039133.0,Pluristem Reports PLX Cells Reduce Fibrotic Processes ,2012-10-17 06:05:00-04:00,PSTI,neutral
1039134.0,Pluristem Issues Letter to Shareholders Highlighting Milestones,2012-10-09 06:16:00-04:00,PSTI,neutral
1039135.0,A Peek Into The Market Before The Trading Starts,2012-10-04 07:27:00-04:00,PSTI,neutral
1039136.0,Pluristem Develops Point-of-Care Thawing Device for PLX Cells ,2012-10-04 06:02:00-04:00,PSTI,neutral
1039137.0,Pluristem Closes 8M Unit Offer at $4 Each,2012-09-19 10:07:00-04:00,PSTI,neutral
1039138.0,Morning Market Losers ,2012-09-13 10:36:00-04:00,PSTI,negative
1039139.0,"Pluristem Offering Stock Warrants, 8M Units Priced at $4M",2012-09-13 09:02:00-04:00,PSTI,neutral
1039140.0,Benzinga's Top Pre-Market Losers,2012-09-13 08:22:00-04:00,PSTI,negative
1039141.0,"Stocks To Watch For September 13, 2012",2012-09-13 04:26:00-04:00,PSTI,neutral
1039142.0,Pluristem Announces Proposed Public Offering of Common Stock; Warrants to Purchase Common Stock  ,2012-09-12 16:02:00-04:00,PSTI,neutral
1039143.0,Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use ,2012-09-05 05:59:00-04:00,PSTI,positive
1039144.0,DS Brokerage Initiates Plusristem with Buy and $7.80 PT -Globes,2012-09-04 10:52:00-04:00,PSTI,neutral
1039145.0,Pluristem Files for Orphan Drug Status With U.S. FDA for Use of PLX Cells in Treatment of Aplastic Anemia ,2012-08-30 07:01:00-04:00,PSTI,neutral
1039146.0,A Peek Into The Market Before The Trading Starts,2012-08-21 07:23:00-04:00,PSTI,neutral
1039147.0,Pluristem and Charité Berlin-Brandenburg Center for Regenerative Therapies Renew Five-Year Collaborative Research Agreement,2012-08-21 06:05:00-04:00,PSTI,positive
1039148.0,Pluristem Spiking Higher,2012-08-14 10:09:00-04:00,PSTI,neutral
1039149.0,Pluristem Spiking Higher,2012-08-10 14:25:00-04:00,PSTI,neutral
1039150.0,A Peek Into The Market Before The Trading Starts,2012-08-07 07:20:00-04:00,PSTI,neutral
1039151.0,Pluristem Receives Approval to Commence a Phase I/II Study for Muscle Regeneration in Germany,2012-08-07 06:19:00-04:00,PSTI,positive
1039152.0,Life of Cancer Patient Suffering From Bone Marrow Failure Saved Following Treatment With Pluristem's PLX Cells,2012-08-06 08:06:00-04:00,PSTI,negative
1039153.0,Maxim Group Initiates Coverage on Pluristem Therapeutics at Buy,2012-07-25 09:11:00-04:00,PSTI,neutral
1039154.0,WBB Securities Downgrades Pluristem Therapeutics from Speculative Buy to Hold,2012-07-24 08:57:00-04:00,PSTI,positive
1039155.0,A Peek Into The Market Before The Trading Starts,2012-07-23 07:20:00-04:00,PSTI,neutral
1039156.0,Pluristem Therapeutics Set to Enter Bone Marrow Disease Market as it is Preparing to Apply for Orphan Drug Status With the FDA for the Treatment of Aplastic Bone Marrow ,2012-07-23 06:38:00-04:00,PSTI,neutral
1039157.0,"Benzinga's Microcap Movers for Thursday July 19, 2012",2012-07-19 16:32:00-04:00,PSTI,neutral
1039158.0,Earnings Scheduled For June 21,2012-06-21 02:17:00-04:00,PSTI,neutral
1039159.0,Pluristem CEO Says in Talks to License PLX Blood-Circulation Treatment -Bloomberg,2012-06-19 17:03:00-04:00,PSTI,neutral
1039160.0,Pluristem Therapeutics' Cell Therapy Broadens Addressable Markets - Demonstrates Systemic Effectiveness of Intramuscular Delivery ,2012-06-19 07:29:00-04:00,PSTI,neutral
1039161.0,Pluristem's CEO Letter to Shareholders  ,2012-05-23 07:01:00-04:00,PSTI,neutral
1039162.0,"Needham Initiates Coverage on Pluristem Therapeutics at Buy, Announces PT of $5",2012-05-22 06:51:00-04:00,PSTI,neutral
1039163.0,Cardiac Function in Pre-Clinical Diabetic Diastolic Heart Failure Subjects Improved by Pluristem's PLX Cells ,2012-05-15 07:03:00-04:00,PSTI,negative
1039164.0,Pluristem Therapeutics Trading 23.5% Higher on Heavy Volume; Currently at $2.89,2012-05-09 09:58:00-04:00,PSTI,neutral
1039165.0,"From Earlier, Compassionate Use of Pluristem's PLX Cells Saves the Life of a Child After Bone Marrow Transplantation Failure ",2012-05-09 09:57:00-04:00,PSTI,neutral
1039166.0,Pluristem Awarded a $3.1 Million Grant by Israeli Government ,2012-04-30 06:35:00-04:00,PSTI,positive
1039167.0,Pluristem Receives U.S. FDA Clearance for Phase II Clinical Trial in Intermittent Claudication  ,2012-04-17 07:04:00-04:00,PSTI,neutral
1039168.0,Benzinga's Top Pre-Market Gainers,2012-03-20 08:13:00-04:00,PSTI,positive
1039169.0,A Peek Into The Market Before The Trading Starts,2012-03-20 07:14:00-04:00,PSTI,neutral
1039170.0,Pluristem's PLX Cells Effective in Treatment of Acute Myocardial Infarction in Animal Trial ,2012-03-20 07:03:00-04:00,PSTI,positive
1039171.0,A Peek Into The Market Before The Trading Starts,2012-02-07 07:21:00-05:00,PSTI,neutral
1039172.0,Pluristem to Expand Research & Development of Radiation Exposure Treatment  ,2012-02-07 06:37:00-05:00,PSTI,positive
1039173.0,Pluristem Awarded a $2.4 Million Grant From Israeli Government ,2012-01-18 07:15:00-05:00,PSTI,positive
1039174.0,FDA Warns About Unproven Stem Cell Claims,2012-01-08 19:11:00-05:00,PSTI,negative
1039175.0,"Global Hunter Initiates Pluristem Therapeutics at Speculative Buy, $5 PT",2011-12-09 07:47:00-05:00,PSTI,positive
1039176.0,Pluristem Announces Positive 12-Month Data From the Use of PLX-PAD for the Treatment of Critical Limb Ischemia  ,2011-11-03 06:40:00-04:00,PSTI,positive
1039177.0,Pluristem Therapeutics Files $150M Mixed Securities Shelf,2011-09-26 17:04:00-04:00,PSTI,positive
1039178.0,Pluristem Says Cells Potentially Effective For Acute Radiation,2011-09-07 07:00:00-04:00,PSTI,positive
1039179.0,Pluristem's PLX Cells Found to Have Potential to Treat Acute Radiation Syndrome  ,2011-09-07 07:00:00-04:00,PSTI,positive
1039180.0,Pluristem's PLX Cells Receive Orphan Drug Status for Treatment of Buerger's Disease,2011-08-25 07:00:00-04:00,PSTI,neutral
1039181.0,Pluristem Receives Orphan Designation for Burgers Disease Therapy,2011-08-24 11:07:00-04:00,PSTI,neutral
1039182.0,"NASDAQ Top Movers; Kandi, YRC, Coffee Holding, Pluristem",2011-07-12 12:00:00-04:00,PSTI,positive
1039183.0,Pluristem Therapeutics Eyeing Daily Highs,2011-07-11 14:49:00-04:00,PSTI,neutral
1039184.0,High-Flying Breakout Plays for 7/7,2011-07-07 12:12:00-04:00,PSTI,positive
1039185.0,Pluristem Therapeutics Pops on Licensing Pact ,2011-06-20 16:47:00-04:00,PSTI,neutral
1039186.0,Pluristem up Over 10% After Announcing Agreement with United Therapeutics Corporation ,2011-06-20 08:56:00-04:00,PSTI,positive
1039187.0,Oppenheimer Maintains Outperform Rating On Pluristem Therapeutics,2011-06-02 09:18:00-04:00,PSTI,neutral
1039188.0,"Top Narrow Based Indexes For May 18 (NGLPF, CREE, PSTI)",2011-05-18 11:40:00-04:00,PSTI,positive
1039189.0,"Top five companies Stocks in the Specialty Chemicals industry- ROC, NLC, CYT, FOE, ECL",2011-04-28 09:14:00-04:00,PSTI,negative
1039190.0,Pluristem Announces Six-Month Follow-Up Results of Its Phase I Trials (PSTI),2011-04-13 07:20:00-04:00,PSTI,neutral
1039191.0,"Top Narrow Based Indexes For April 11 (REE, GLBC, PSTI)",2011-04-11 10:54:00-04:00,PSTI,positive
1039192.0,A Peek Into The Market Before The Trading Starts,2011-04-06 07:23:00-04:00,PSTI,neutral
1039193.0,Pluristem Therapeutics Increases Testing of PLX Cells For Radiation (PSTI),2011-04-06 07:05:00-04:00,PSTI,neutral
1039194.0,Pluristem Therapeutics Ticks Higher On CNBC Chatter (PSTI),2011-04-05 13:36:00-04:00,PSTI,neutral
1039195.0,Pluristem Therapeutics Falls 26% On News Of Secondary Offering (PSTI),2011-01-27 12:31:00-05:00,PSTI,neutral
1039196.0,Pluristem Prices 11M Share Public Offering at $3.25,2011-01-27 09:34:00-05:00,PSTI,positive
1039197.0,"Low Priced Stocks on the Move (IO),(ELN),(QUIK),(PSTI),(FBN)",2011-01-25 10:48:00-05:00,PSTI,negative
1039198.0,"Low Priced Stocks on the move (ELN),(QUIK),(FBN),(PSTI),(IO)",2011-01-25 10:34:00-05:00,PSTI,negative
1039199.0,"Small Cap Stocks on the move:(CRDC),(WAVX),(MNI),(CXDC),(BSDM),(ONCY) more below",2011-01-18 22:44:00-05:00,PSTI,neutral
1039200.0,"15 Low Priced Stocks to watch on the move (CRDC),(FXEN),(RDNT),MOSY) more below",2011-01-10 17:41:00-05:00,PSTI,negative
1039201.0,"Morning Market Movers (GENE, ACAD, PSTI, PLA)",2011-01-10 10:09:00-05:00,PSTI,neutral
1039202.0,"Top Narrow Based Indexes For January 3 (AVL, ESIO, PSTI)",2011-01-03 11:36:00-05:00,PSTI,positive
1039203.0,Pluristem Therapeutics Raises Approximately $5 Million in Private Placement ,2010-10-12 08:08:00-04:00,PSTI,neutral
1039204.0,Pluristem Pops…Again (PSTI),2010-09-17 10:02:00-04:00,PSTI,neutral
1039205.0,Pluristem Pops on Cell Therapy Data (PSTI),2010-09-14 09:55:00-04:00,PSTI,neutral
1039206.0,Pluristem Therapeutics Pops on EU Grant (PSTI),2010-08-30 11:14:00-04:00,PSTI,positive
1039207.0,Stem Cell Research Company Stocks On the Move,2009-12-02 16:11:00-05:00,PSTI,neutral
